/ /

  • linkedin
  • Increase Font
  • Sharebar

    Aflibercept performance consistent in DME regardless of prior anti-VEGF therapy

    VISTA-DME/VIVID-DME trials evaluate efficacy of treatment with central involvement, BCVA


    The respective percentages for treatment-naïve patients were 15.4%, 36.8%, and 36.1%, Dr. Wykoff noted.

    No major differences were observed among the treatment arms regarding ocular adverse events, serious adverse events, systemic serious adverse events, and ocular inflammation.


    Charles C. Wykoff, MD, PhD

    E: [email protected]

    This article was based on a presentation by Dr. Wykoff at the 2014 meeting of the American Society of Retina Specialists. Dr. Wykoff is a consultant and speaker for and receives research funding from Alcon Laboratories, Allergan, Genentech, and Regeneron.



    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results